We set our sight on a simple, but powerful vision to advance life science services toward a healthier world.
The journey began when Water Street Healthcare Partners and JLL Partners joined forces to acquire and combine the most comprehensive platform of life sciences services in the industry. Together, we are EVERSANA.
We offer more than 500 clients – from start-ups to established global pharmaceutical leaders – the services they need to bring critical therapies to market while improving the lives of patients around the world.
We start with understanding patient and clinician needs, to co-create solutions that integrate behavioral science. Our cloud-based platform delivers personalized support and interventions for each patient’s condition and circumstance.
With over 16 years’ experience and having delivered award-winning solutions across 20 therapy areas in over 49 countries, our multi-disciplinary team create solutions which are scalable, secure and regulatory compliant.
IQVIA (NYSE:IQV) is a leading global provider of information, innovative technology solutions and contract research services focused on helping healthcare clients find better solutions for patients. Formed through the merger of IMS Health and Quintiles, IQVIA applies Human Data Science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes.
Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes. Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click’s lead prescription program is entering into a multi-center, randomized, controlled, parallel-group, phase III FDA registration trial for the treatment of Major Depressive Disorder in adults.
Cognoa’s digital diagnostics and personalized therapeutics improve the timeliness, scale, and effectiveness of behavioral healthcare. Their first clinically-validated mobile application identified autism on average 13 months earlier than the national average and as early as 18 months – when early intervention has the greatest potential for improved life-long outcomes.
Be part of the 150+ person audience of senior executives from digital therapeutic companies, pharma, investors and healthcare professionals
Learn from the industry-defining speaker faculty, comprised of the pioneers of the industry and the most exciting new-comers form Europe, USA and beyond
Hear about the European regulatory landscape, successful go-to-market models and achieving patient engagement at longevity during in-depth presentations and deep-dive panel discussions
“I found this conference eye-opening and had many interesting conversations. I am blown away by the Digital Therapeutics community and its commitment to value-based care”
“DTx is the must attend event in our industry”
“The DTx Series is a fantastic set of meetings. The quality of the investors, entrepreneurs and companies never fails to impress me, and I always leave having learned a lot”
“The conference was tangible, specific and open. I have never been to a conference of this size with such richness of discussion”
“Thanks for catalyzing the industry forward in this emerging field. Looking forward to the next one”
“DTx is an inclusive event, where the participants truly believe that the rising tide will raise all boats”
Anand is a respected global digital health leader—most known for his insights on and experience with technology, strategy and regulatory policy. Anand has been instrumental in WellDoc’s success and the development of BlueStar®. Since joining WellDoc in 2008, he has held core leadership positions that included Chief Data Science Officer, President and Chief Operations Officer. He holds an MS and a PhD in electrical and computer engineering, and an MBA from Carnegie Mellon University.
Kim Baden-Kristensen is the CEO and Co-founder of Brain+, an award winning Danish health tech company specializing in digital therapeutics for neurorehabilitation of disorders and injuries to the Central Nervous System (CNS).
Kim is intensively engaged in digital health care policy debates and initiatives on the European level. He is a founding member of the Digital Therapeutics Partnership, a global non-for-profit with a mission to enhance patient outcomes and quality of care with clinically-validated digital therapeutics.
Kim is an expert within digital therapeutics, with particularly emphasis on neurogame-based rehabilitation and gamified behavioral therapy.
Kim holds an MSc. In Innovation Management from Copenhagen Business School, a Health Care Innovation Management degree from Harvard Business School, and a minor in Cognitive Neuroscience from Copenhagen University.
Francesca Domenech Wuttke, Ph.D. is the Chief Digital Officer of Almirall where she is developing and executing an end-to-end companywide digital transformation. She is responsible for finding use cases across R&D, commercial, manufacturing, finance, legal and HR to apply digital solutions and services to bring efficiencies in terms of time and cost and to open up new business channels for Almirall.
Dr. Wuttke brings with her broad drug development and healthcare expertise in both the US and Europe, with over 20 years of clinical, commercial, strategic and transactional experience. She has worked with diverse organizations including start-ups, consulting, large and specialty pharma as well as academia. Most recently, she led European investments as Managing Director for the MSD Global Health Innovation Fund, LLC. Previously Dr. Wuttke led Almirall´s Corporate Development Strategy team to transact on both med device and pharma M&A opportunities with a new and targeted focus for the company.
Before that Dr. Wuttke worked at Novartis where she was responsible for two Cell and Gene therapy opportunities that were successfully brought into the organization as well as managing the strategy and commercialization for the existing portfolio of cell therapy assets.
Dr. Wuttke holds a Ph.D. in Pharmacology from Weill Cornell Graduate School of Medical Sciences and a BA from Cornell University College of Arts and Sciences.
Previously Studio Director at Gameloft Madrid – a company developing and editing videogames –, Edouard is leading the Tilak Healthcare team. Before heading the Madrid Creation Studio, Edouard successively worked at Gameloft as Project Manager in Paris, then Lead Producer in New Orleans. He was also a writer for TechCrunch France, covering mobile apps, 2.0 web and entertainment topics. In 2011, he co founded Productism, a social commerce website.
Ray joins DIGITALEUROPE with over 20 years of government affairs and communications experience in Brussels and across the EMEA region. Previously, he worked at Microsoft being part of the team responsible for the strategies to improve relations with governments and position the company on socio-economic issues. Ray leads the digital transformation strategy to leverage DIGITALEUROPE’s expertise in key policy areas such as data protection, media, platform and consumer issues to create an important dialogue between industries being disrupted by technology and guidance to European regulators.
Ray leads several Policy and Working Groups helping our members advance important work in areas which includes artificial intelligence, skills development and the free flow of data. Areas that will be vital to unlock the full potential in Europe to deliver jobs, prepare children in education systems to be able to exploit important technologies and ensure Europe is a leader in creating world-class technology companies.
Ray holds citizenship with both Canada and France and is a graduate of McGill University in Political Science.
Edward Cox was appointed as the new Chairman of the Board and the Chief Executive Officer of Dthera in connection with the closing of the EveryStory Transaction. Mr. Cox also continues to serve as EveryStory’s President and Chief Executive Officer and Chairman and a member of EveryStory’s Board of Directors, positions he has held since February 6, 2015. Prior to that, he served as a Vice President and Executive Officer of Apricus Biosciences, Inc., a publicly traded company, since December 2009, in roles leading Commercial Development, Business Development, Investor Relations, and Corporate Development. Mr. Cox holds a Master of Science in Management degree from the Warrington College of Business Administration at the University of Florida.
Dr Ciara Clancy is founder and CEO of Beats Medical, a digital therapeutics company specialising in neurological and CNS conditions.
Clancy holds a degree in Physiotherapy and a PhD in Neurosurgery outcomes. Her entrepreneurial work has been internationally recognised including selection for Forbes 30 under 30, Laureate for Europe in the Cartier Awards and a finalist in the EY Entrepreneur of the Year Awards.
Brent is the CEO and co-founder of Cognoa, an AI-based digital precision medicine behavioral health platform. Cognoais developing innovative digital diagnostics and digital therapeutics to change the standard of care for pediatric behavioral health and improve outcomes by enabling earlier diagnosis, treatment, and increased engagement. Brent has over 20 years industry experience working with diagnostics, therapeutics and digital consumer health. Prior to Cognoa, Brent was the co-founder and COO of WellnessFX, an award-winning digital health company that increased patient engagement by providing direct-to-consumer diagnostics and integrated telemedicine. Before working in digital health, Brent worked in product and commercial roles in Novartis, Nektar, Roche and Lily.
Dr. Parks’ research focuses on self-help methods for increasing well-being via books and digital technology. She is Chief Scientist for tech startup Happify, which brings the cutting edge in research-based well-being interventions to large businesses, health plans, and consumers. Her research spans across the whole spectrum of wellness, from non-distressed consumers to stressed employees, sufferers of chronic health conditions, and individuals with depression and/or anxiety. She works to pioneer new methodology in the study of digital therapeutics, especially when it comes to outcomes assessment. Her work has been published in peer-reviewed journals, and in addition to editing three books, she is also an Associate Editor at the Journal of Positive Psychology.
Dr. Maroof Ahmed is a medical doctor who graduated from Imperial College London with dual degrees in Medicine and Business Management. He is the co-founder and COO of Digital Therapeutics.
Maroof spent 4 years conducting academic research in the fields of neurology, behavioural change, digital health and smoking cessation. He has published multiple peer-reviews papers on these topics and also acts as a reviewer for JMIR.
Whilst training to become a doctor, Maroof saw the impact smoking had on the lives of the patients around him and wanted to make a difference. So together with his co-founders, they put on hold their clinical careers to pursue Quit Genius full-time. This was a tough decision but they made this choice as it will allow them to make an impact on the lives of people worldwide at scale.
Dennis is VP of business development & corporate finance at Kaia Health, a start-up developing individualised digital therapies for chronic diseases with a focus on backpain and respiratory conditions.
Prior to joining Kaia Health, Dennis was the COO of Oro de Cacao, where he led the scale-up process and financing rounds, and advised clients on Private Equity and Real Estate investments at 1875 FINANCE.
Donna became the Executive Director of EFNA in June 2012. Donna’s training is in Journalism, but she has worked with patient organisations in the neurological sector – in various roles – since leaving university. This included work with the European Migraine and Headache Alliance [EMHA] and the Migraine Association of Ireland [MAI], as well as being a representative to the Neurological Alliance of Ireland. Donna oversees the strategic direction of EFNA and leads in the creation and implementation of its annual workplan, projects and activities. Since joining EFNA, Donna has led the development of some of EFNA’s current keynote initiatives such as its MEP Interest Group on Brain, Mind and Pain and Training Initiatives for Neurology Advocates. She is also active in representing EFNA and the neurology patient community externally, including as a current Board Member of the European Brain Council and as a Member of the European Academy of Neurology’s European Affairs Sub-Committee.
Hakim is a Co-Founder and chief executive of Closed Loop Medicine. He joined CLM from the Northern Health Science Alliance Ltd, the pan-Northern health partnership which brought together for the first time 20 research-based NHS hospitals, the North’s Academic Health Science Networks and Universities to collaborate on improving health outcomes across the North.
As the founding CEO of the NHSA, Hakim was instrumental in raising the profile of the region in parliament, with investors and the media to help focus resources on improving healthcare services for the 15 million population living in the North and its eight great cities. Central to the NHSA’s mission was to raise awareness of the region’s high mortality rates and to seek national solutions to improve these morbidity levels by working with all local agencies to improve health – and therefore wealth and well-being -outcomes.
Hakim was also highly successful in working with companies in the North to attract substantial domestic and overseas investment into the region’s life science sector, one of the most vibrant in the country.
Having worked with specialist drug and digital companies all around the world, he has a deep understanding of innovation systems integration.
Hakim started his career at PA Consulting, where he co-managed the company’s translational medicine team. During his time at PA, he was seconded to the UK Government where he worked as the Chief Operations Officer and was a founding member of the UK Department of International Trade (DIT) Life Sciences Organisation (LSO).
He holds a PhD from the University of Cambridge and in 2017 he was awarded an OBE for services to Healthcare Technology and the Economy.
Matthias is a physician by training and holds a medical doctorate degree from the University of Ulm, Germany. He has gained both inpatient and outpatient medical expertise in various healthcare systems around the world. Matthias joined GAIA 17 years ago and takes the responsibility for the national and international business development and licensing activities with payer and physician organisations as well as industry partners. And when not travelling the world for business, he travels the world for leisure.
Workshops - Tuesday June 9th
- Workshop 1: The Business of Digital Therapeutics
- Workshop 2: A Deep Dive into the European Regulatory Landscape
Matthias Zenker, Partner, GAIA AG
Kim Baden-Kristensen, Co-Founder & CEO, Brain+
Edward Cox, Chief Executive Officer, Dthera Sciences
The digital therapeutics industry has proved to be broad and multifaceted. This had led to numerous approaches in building a DTx business, validating the product and taking it to market.
This workshop, led by leaders within the industry, will explore the various business models, routes to market and how the preferred business model may change from country to country
Leave this workshop with:
- A deeper understanding of the various business models demonstrated by digital therapeutic companies
- Up-to-date information on business models of varying successes in the current industry
- An understanding of the current successes of business models in varying countries across Europe
- A clear understanding of current routes to market and their intricacies
- Your questions answered by industry leaders and your peers
Jessica Schull, European Lead, Digital Therapeutics Alliance
Ray Pinto, Policy and Member Relations Director, DIGITALEUROPE
The regulatory landscape across Europe is complex and varied in comparison to the U.S counterparts. With numerous regulatory bodies and different requirements for each, scaling across Europe can prove challenging.
This workshop, led by leaders of the industry, will provide you with answers to your key questions on European Regulation, new inbound regulatory changes and how best to move forward with achieving pan-European approval for digital therapeutics.
Leave this workshop with:
- A clear understanding of the European regulatory landscape
- A deeper understanding of how best to tackle the varying Regulatory bodies across Europe
- An understanding of how the new MDR changes will affect the DTx industry and how best to adhere to them
- Being in the know for future plans for a pan-European regulation for digital therapeutics
- Your questions answered by industry-leading experts and your peers
Agenda to be Announced
Venue - London, UK
Last year the Summit was held at the Grand Connaught Rooms, located in the heart of Covent Garden.
This year’s venue will be announced when we launch DTx London on Monday, January 27th.
The DTx summits are the premier events for senior executives from DTx companies, Pharma, Investors, HCPs and Payers.
DTx Europe 2019 is the fourth summit in the series, the first three were sell-outs. We are expecting 100 people at the summit in London, which is what our attendees and sponsors tell us is the optimum size.
We believe that getting the right mix of sponsors is critical for a successful summit for you and our attendees. The DTx summit provides a rare opportunity to showcase your business to a world class audience.
You will be impressed with our service and truthfulness. We will be honest with you throughout the process from deciding which option is right for you to delivery on-site.
With four companies confirmed pre-launch, sponsor and supporter spaces are selling fast. Get in touch today to learn more to avoid missing out!
Register for the Event
For pricing and booking options please click the button to go to the registration page.